Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (51)

2021

  1. Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients

    Annals of Hematology, Vol. 100, Núm. 4, pp. 1023-1029

2020

  1. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073

  2. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

    Annals of Hematology, Vol. 99, Núm. 4, pp. 799-808

2019

  1. Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes' army

    Future Science OA, Vol. 5, Núm. 10

2018

  1. A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

    Leukemia and Lymphoma, Vol. 59, Núm. 12, pp. 2888-2895

  2. Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia

    Immunotherapy, Vol. 10, Núm. 6, pp. 491-499

  3. Update on posttransplant lymphoproliferative disease

    Current Opinion in Nephrology and Hypertension, Vol. 27, Núm. 6, pp. 440-444

2017

  1. Common variable immunodeficiency-associated granulomatous and lymphocytic interstitial lung disease successfully treated with a combination regimen of rituximab and azathioprine

    Medicina Clinica, Vol. 149, Núm. 7, pp. 312-313

  2. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

2016

  1. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity

    Immunologic Research, Vol. 64, Núm. 2, pp. 548-557

  2. Obinutuzumab in follicular lymphoma

    Drugs of Today, Vol. 52, Núm. 12, pp. 643-651

2015

  1. Antidesmocollin 1 autoantibody negative subcorneal pustular dermatosis-type IgA pemphigus associated with multiple myeloma

    British Journal of Dermatology

2014

  1. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial

    Haematologica

  2. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial

    Haematologica, Vol. 99, Núm. 3, pp. 505-510

  3. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: A retrospective study of the Spanish experience

    Annals of Hematology, Vol. 93, Núm. 9, pp. 1551-1558

  4. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111

  5. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial

    British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336

2013

  1. A new modified prophylactic scheme against liposomal cytarabine-induced arachnoiditis in adult patients with lymphoma

    Leukemia and Lymphoma

2012

  1. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain

    Leukemia Research, Vol. 36, Núm. 6, pp. 709-714

2010

  1. Anemia ferropénica: Estrategias dietéticas para su prevención

    Actividad Dietetica, Vol. 14, Núm. 2, pp. 67-71